Therapeutic Drug Monitoring and Safety of Voriconazole Therapy in Patients with Child-Pugh Class B and C Cirrhosis: A Multicenter Study.
International Journal of Infectious Diseases（2018）
Abstract
•This is the first study of voriconazole pharmacokinetics and safety in cirrhosis patients.•Voriconazole Cmin for the standard dose was 6.95±3.42mg/l in cirrhosis patients.•Voriconazole Cmin was 4.02±2.00mg/l in cirrhosis patients receiving the halved dose.•Voriconazole Cmin was related to INR and CYP2C19 inhibitor use in cirrhosis patients.•Most adverse events developed within 7days after starting voriconazole treatment.
MoreTranslated text
Key words
Voriconazole,Trough concentration,Liver cirrhosis,Therapeutic drug monitoring,Adverse events
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined